No description available.

Ficus thonningii is a nutraceutical that is extensively used in ethnomedicine. Nursing mothers use F. thonningii leaves as nutritional and medicinal supplements and are at risk of exposing their infants to its constituent phytochemicals. The exposure of the sensitive neonatal gastrointestinal tract (GIT) to these phytochemicals can result in irreversible changes in growth and development. The objectives of this study were to determine the effects of crude F. thonningii extracts on; growth, morphology and morphometry of the abdominal viscera and clinical biochemistry of neonatal rats. Forty, suckling Sprague Dawley rats of either sex were randomly divided into 5 groups. Each group was orally gavaged once daily with either low (50 mg/kg b.w) or high (500 mg/kg b.w) doses of aqueous or methanolic extracts of F. thonningii, for 7 days. The control rats received distilled water. The pups were euthanased and tissues were collected and weighed. Samples of the liver, caecum and proximal small intestine were preserved and processed for histology. Plasma biochemical parameters were analysed colorimetrically. Data was presented as means + SD. F. thonningii extracts exhibited trophic effects on the stomach and ceacal mucosa of rats but had no significant growth-promoting effects on the small intestine and visceral organs. Histological analysis of the intestine, liver and caeca revealed no mucosal damage. Clinical chemistry parameters were not abnormally altered. There was a significant decrease (p<0.05, ANOVA) in the plasma concentrations of basal (non-fasting) glucose in the pups on the high methanolic extracts. However, the triglyceride and cholesterol levels were unaltered by the treatments. The findings suggest that F. thonningii extracts exhibit trophic effects on the mucosal layers of the stomach and caecum. F. thonningii extracts also possess glucose-lowering activity. At low doses, F. thonningii extracts can be safely used without the risk of any disruption in the structural integrity of the neonatal rat GIT and function of the liver and kidneys.

Tuberculosis (TB) is the leading cause of death in individuals infected with human immunodeficiency virus (HIV) in several African countries, including South Africa. HIV-positive individuals do not have the immune system resources to keep TB in check and are as much as 30 times more likely to develop active TB than people who are HIV-negative. Many people infected with HIV develop TB as the first manifestation of AIDS and TB accelerates disease progression in HIV-positive individuals. HIV and TB pathogenesis are thus inextricably intertwined so that it is necessary for medical practitioners to have an understanding of the dynamics and treatment of HIV-TB coinfection. At present the question remains as to whether the best time for coinfected individuals to start antiretroviral treatment for HIV is at the beginning, the peak, or after the completion of the TB treatment phase. This dissertation was undertaken with the aim of obtaining some clarity on this question by creating a mathematical model of HIV-TB coinfection and its treatment. This needs an understanding of the biological interactions; therefore the dissertation begins with a discussion of the biological mechanisms of HIV, the human immune system, TB and the drug therapies for each disease. Thereafter a brief introduction to mathematical modelling reviews basic HIV models, which are then modified to include HIV drug therapy. Analyses and simulations of these models were carried out, which yielded some insights into the dynamics of HIV and HIV therapy. Finally HIV-TB coinfection is introduced by reviewing a previously developed model. Based on all the models reviewed, a model for coinfection is developed which includes treatment for HIV and TB. Numerical simulations suggest that, if HIV disease progression is at an advanced stage of the immune system collapsing towards AIDS, with low T-cell count and high viral load, it is necessary to treat for both diseases simultaneously to ensure a positive survival prognosis for the coinfected individual. However, if disease progression is in the early stages of AIDS, with T-cell count and viral load beginning to display signs of the immune system collapse but still at reasonable levels relative to advanced stages, it need not be necessary to treat both diseases simultaneously. TB can be treated first, and upon completion HIV treatment can be initiated thus sparing the coinfected individual from the compounded side-effects and drug-drug interactions which usually result from simultaneous treatment. / Thesis (M.Sc.)-University of KwaZulu-Natal, 2007.

Thesis (M.S.)--University of Michigan, 1951.

Chun Sing Chu. / Thesis (M.Phil.)--Chinese University of Hong Kong, 1992. / Includes bibliographical references (leaves 139-149). / Acknowledgements --- p.i / Abstract --- p.ii / Abbreviations --- p.vi / Chapter Chapter 1 --- General Introduction --- p.1 / Chapter Chapter 2 --- "Development of Polyclonal Antibodies against 5α-Estrane-3β,17α-diol" / Chapter 2.1 --- Introduction --- p.39 / Chapter 2.2 --- Materials and Methods --- p.45 / Chapter 2.3 --- Results --- p.55 / Chapter 2.4 --- Discussion --- p.64 / Chapter Chapter 3 --- "Development of Monoclonal Antibodies against 5α-Estrane-3β,17α-diol" / Chapter 3.1 --- Introduction --- p.69 / Chapter 3.2 --- Materials and Methods --- p.86 / Chapter 3.3 --- Results --- p.107 / Chapter 3.4 --- Discussion --- p.126 / Chapter Chapter 4 --- General Conclusion --- p.134 / References --- p.139

A retrospective research study was conducted to determine the effectiveness of the Drug Evaluation and Classification Program (DECP) procedures in order to identify subjects under the influence of specific drug categories. The investigator wanted to determine if the procedures are reliable and whether a drug recognition expert (DRE) can properly apply the DECP procedures to consistently identify the drug category and have that opinion supported by toxicology. A total of 324 enforcement drug influence evaluations (DIEs) were obtained from the DRE data tracking system (DRE-DTS) that is maintained through the National Highway Traffic Safety Administration (NHTSA). Toxicology results related to each DIE were compared to the DRE??s drug category prediction. The objectives of the study were to determine if the 12-step DECP process enables DREs to identify drug categories and those most frequently identified and confirmed in Texas. Using the DECP, the DRE??s ability to identify specific drugs according to categories and to have the identification supported by toxicology was moderately accurate at best. Of the 324 evaluations that had toxicology results, the DRE correctly identified drug categories as follows: depressants, 60.5%; stimulants, 32%; hallucinogens, 12%; PCP, 46.6%; narcotic analgesics, 51.6%; inhalants, 14.2%; and cannabis, 64.9%. To determine which drug categories were called most frequently, the enforcement DIEs were analyzed according to each specific category. The investigator found the following drug categories were most frequently called by DREs who evaluated subjects: depressants, 182; cannabis, 142; narcotic analgesics, 83; stimulants, 62; PCP, 18; inhalants, 4; and hallucinogens, 1. To determine which drug categories were most frequently confirmed through toxicology, the enforcement DIEs were analyzed for the number of confirmations for each specific drug category. The investigator found the following drug categories were most frequently confirmed through toxicology: depressants, 176; cannabis, 140; stimulants, 106; narcotic analgesics, 99; PCP, 26; hallucinogens, 8; and inhalants, 4. The investigator was able to determine, based on the DRE-DTS data, that Texas DREs are only moderately accurate in identifying drug categories when utilizing the DECP procedures in enforcement settings. Furthermore, the DRE??s prediction of drug category was not consistently supported by toxicology results obtained from evaluated subjects.

Thesis (Ph.D.)--University of Florida, 2004. / Typescript. Title from title page of source document. Document formatted into pages; contains 139 pages. Includes Vita. Includes bibliographical references.

The general aim of this thesis was to examine the effect of interventions on the usage of inappropriate and hazardous multi-medication in the elderly ≥75 years with ≥5 drugs. Methods: Paper I describes a cluster randomization of nursing homes, the outcomes were; number of drugs, health status and evaluations. A randomized controlled trial concerning elderly in ordinary homes was performed in paper II and the outcomes were; EQ-5D index, EQ VAS and prescription quality. In paper III a cohort study was carried out and the outcomes were; medication appropriateness index, EQ-5D index and EQ VAS. In paper IV, registered nurses from the nursing homes study were interviewed in a descriptive study with a qualitative approach. Results:There was a significant reduction of number of drugs used per patient at the intervention nursing homes (p&lt;0.05). Monitoring and evaluation of medications were significantly more frequent at the intervention homes (p&lt;0.01). The registered nurses at the nursing homes described a self-made role in their profession and the leadership was not at sight. Drug treatment seems to be a passive process without own reflection. Extreme polypharmacy was persistent in all three groups of elderly living in ordinary homes and there was an unchanged frequency of drug-risk indicators. In the cohort study a lower medication quality was shown to be associated with a lower quality of life. EQ-5D index was statistically significantly different among the groups as was EQ VAS. Conclusion: The nursing home study showed an extreme shortage of monitoring of health status and surveillance of the effects of drugs in the elderly. More attention must be focused on the complexity of the nursing process; medication management must be promoted in teamwork with the physician. The resistance to change prescriptions in accordance with the intervention underlines the need of new strategies for improving prescription quality. Since medication quality is related to the patients’ quality of life, there is immense reason to continuously evaluate every prescription and treatment in shared decision with the patient.

Thesis (Ph.D.)--Pardee Rand Graduate School, 2009. / Title from PDF t.p. Includes bibliographical references.

Thesis (Ph. D.)--University of Washington, 2007. / Vita. Includes bibliographical references (leaves 45-50).